Stevanato Group (STVN)
(Delayed Data from NYSE)
$19.66 USD
+0.46 (2.40%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $19.65 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STVN 19.66 +0.46(2.40%)
Will STVN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for STVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STVN
USNA vs. STVN: Which Stock Should Value Investors Buy Now?
USNA or STVN: Which Is the Better Value Stock Right Now?
STVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
TAK or STVN: Which Is the Better Value Stock Right Now?
Other News for STVN
Analysts Offer Insights on Healthcare Companies: Iradimed (IRMD), Stevanato Group (STVN) and Ascendis Pharma (ASND)
Morgan Stanley Keeps Their Hold Rating on Stevanato Group (STVN)
Analysts Offer Insights on Healthcare Companies: Stevanato Group (STVN), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fillĀ® Syringes and Cartridges
Stevanato: Destock Pressures, Long-Term Upside